OPTIMIZATION OF DRUG THERAPY IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH PRESERVED CHRONIC HEART FAILURE

The article presents the results of a study on optimizing therapeutic strategies aimed at reducing pulmonary arterial pressure, correcting left ventricular diastolic dysfunction, and remodeling the pulmonary vascular network. Issues of safety, optimal timing of therapy initiation, dosing, and monitoring of efficacy are considered. It is concluded that although there is currently no clear standard for pharmacological treatment of pulmonary hypertension in HFpEF, a comprehensive approach using both new and traditional drugs can significantly improve hemodynamics, quality of life, and long-term prognosis in these patients.